Pfizer (PFE) Income Statement

Click line-items for a historical chart and %

Revenues
Cost of sales
Selling, informational and administrative expenses	3.56B
Research and development expenses	1.88B
Amortization of intangible assets
Acquisition-related in-process research and development charges
Restructuring charges and certain acquisition-related costs	531M
Other deductions--net
Income from continuing operations before provision for taxes on income	1.6B
Provision for taxes on income	284M
Income from continuing operations	1.32B
Income from operations--net of tax
Gain on sale of discontinued operations--net of tax
Discontinued operations--net of tax	0
Net income before allocation to noncontrolling interests	1.32B
Less: Net income attributable to noncontrolling interests	0
Net income attributable to Pfizer Inc.	1.32B
Income from continuing operations attributable to Pfizer Inc. common shareholders	0.22
Discontinued operations--net of tax (in dollars per share)	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	0.22
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	0.22
Discontinued operations--net of tax (in dollars per share)	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	0.21
Basic (in shares)	6.07B
Diluted (in shares)	6.14B
Cash dividends paid per common share (in dollars per share)	0.3

Entities mentioned with PFE

View All Entities